Watch 2 videos about 30 minutes and answer to few questions.

*********** **** **************** nameProfessor ***************************** gene editingCRISPR-Cas9 ** * gene-altering ********* **** is ********** * *** ** ******** ** the ********** ********* ** ** **** ********* less expensive and **** precise than ***** *** *********** ********** *** ** offers * broad ******* of ********* **** in several fields * **** ***** of ******** uses exists **** ** *** ********** ** genetic ************* treatment *** ********** ** ******* ************ ** **** ** *** *********** ** **** ****** *** yield *** ********** ** drought Even ***** the ********** ***** ** **** ********* ************* ** **** poses ethical questions Bacteria which *** very ***** ************* ******** have ******* innate ********* ************ **** **** **** ********** for *** ** *** ****** ************* innovation These microorganisms employ ************** *** which ** * *********** relative ** *** as well as ******** Cas peptides ** defend themselves ******* viral ********** In order to ****** ********* *** microbes slice ***** ******* materialand ***** parts ** **** ********** theirgenomes ***** may ************ ** ******** ** a defense toolagainst *** colonization ** ***** ******* ****** again ** *** future This ***** ***** ** ********* ********* issues ********** ****** gene editing *** ***** argues **** CRISPR is not a **** **** *** ** use ** humansThe *********** ********* is **** up ** *** key ******** **** ******* cooperatively ** **** * change ** the ********* **** ***** *** Cas9is ** ****** ************* as * *** ** 'double ****** splicers' ***** *** ***** *** DNA ****** helix ** * ******* **** ** *** ********** ******** ****** ** DNA ** ** inserted ** ******* as ****** There ** a ****** *** ** RNA known as guide *** (Fan ***** The **** *** ** director ** a ******** ****** *** cas9 ****** will ****** *** *** ****** ** reduce ***** ** ****** ** as ** bind ** * specific ************* **** ******* **** first ****** *** ********* that ******** **** combined **** ****** sequence ** ********** the chromosome **** ***** *** ***** * complementarypair *** ****** ********* *** be **** ** *********** ************* ** single ** ******** ******* sequences *** experts **** **** ** ************ ******** *********** of ****** **** **** modification *** ******* ***** ******** *** issue can be ********* from two ********* sensitive ****** ******** ****** **** ******* has * *********** **** ***** ** ************ * ******* applying ** ** alter ***** ***** under *** ****** circumstance ** ********* wrong First ** *** early **** engineering on ****** has ******** ****** *** ******* the ***** ********* *** **** ** the ******* ***** of the ********** ************ ******** *** experiment ** ** ******* ** * ********** ************ ** is ******* reckless ***** *** so **** ******** *** **** carried to ********* the ****** of editing any human gene ** *** experiment ** Jiankui ****** *** CCR **** making *** ***** ********* to **** ******* as *** **** ******** *** **** of ***** ******** by *** ****** The ****** ** unethical *** **** ***** ********** ****** ** ******** *********** Moreover it ** ***** ** **** *** ***** ****** in ** ******* to manage any ********* ********** ***** **** ***** are ***** *********** ***** ******* ******* ******* *** ***** hand ****** **** is * ******** **** **** *** ** ******* ** ******** **** sequences **** *** ********** **** ****** *** **************** ********** **** is especially ********** ********** if ***** *** ** current effective ******* ****** **** ******* *** ******* been ******* in ******* patients ********** ********* *********** ****** ********** **** as sickle cell ******* as **** ** ******* ******** genetic ******* that ********** with vision and ********** ********* ***** of ******* ******* ****** ****** applying ** ** ****** * believe ******** research should ** **** to ********* ******* ****** safety Additionally *** practice ****** ** strictly ********* ** ********* government *** ******* ******** to ****** *** human population ******** from *** CRISPR technique All ** *** CRISPR **** editing is * potentially ******** **** that *** ***** positive outcomes or ********* forms ** ******* When ** ***** ** applying ** ** ***** ** ** ******* ** ***** **** the ******** ***** ** **** ** *** ****** ********** is not *** ***** to ***** ****** **** ******* ***** ***** *** **** ************ research *** ********* on the ***** (Belluz ************* ****** gene ******* *** have *********** ******* ******** ** is *** yet safe to be **** for human ******* **** ** ******* ********* ********** **** ***** that during *** process ** gene ******* *** ********** modification *** **** ***** *** ******* ****** ***** parts ** the ********** ******* area ** concern ** the **** **** the ********* *** edit genes acting ** *** **** *** life-threatening ******* ******* 2018) **** **** ***** *** **** ****** to ** **** ** * ***** ****** ********** ****** ** taken ****** while ********** ********* ***** of clinical ****** ** ****** *** **** ** **** to use ** *** ****** especially ** ****** ****** ********** ********* *********** can ***** *** things ***** *** ********** ********* health outcomes **** *** process ** ****** ********** ********** has different ethical ************** *** to *** potential ************** risks **** ** ***** ** ******** *** ** the most essential ******* considerations is that *** ********** **** ******** the ******* ********** ***** ***** must ** given **** ************* since **** **** *** potential to **** living ****** ** the ecosystem The ************** ** *** *********** ********** is ******* **** ****** since ** *** *** potential ** ***** ********** *********** that *** ** harmful ******* of *** precision **** ***** *** *********** system *** ******* genetic *********** ** ** ************ ********* ** recognize *********** *********** ********* ***** **** **** **** *** ********** *** ** control these ******* **** they **** ******* the ****** ********** ***** * further ******* ** *** control of ************ ******** ****** ***** *** * variety ** ************* ********* ** ************ ** the ******** *********** ******* ******* *** ********** as **** as the adoption ** informed ********** ******* ******* ************ operations ** ******* ***** *** ********** ******* ********** ******* ******** ******* are *** **** ***** ***** *** ******* *** *********** ********** *** ***** alterations *** adverse ******* it ** ******** **** unforeseen *********** **** ** ****** ** *** **** *********** ************ ***** *** ************ in ************ ******** ******* ********** in ***** ***** ******* ***** ** ****** on ** multiple *********** ********** 2016) ********* *** ******** ** ****** ** ****** ** a **** *** ********* **** **** ******** ******* ** **** as government ******** ** protect *** human ********** **** *********** ********* ***** ************ ********** ****** ** * **** ********** breakthrough that ******* the entire research ********* ** *** potentially ** applied ** **** areas ******** **** *********** crops ** ******* **** ** ******* *** **** used an ****** the cas9 **** can *** *** edit ******** *** ********* *** ** *** greater ************* **** *********** **** ********* *** ******** ** ****** Using ****** ** **** ***** genes ** * ********* ***** ***** ***** ** limited ******** ********** *** ****** Moreover ******* **** ******** **** the technique *** *********** ****** in ********** ************ ** ***** ****** ** a **** for * severe condition **** as ****** Generally CRISPR ** *** *** ***** ** ** applied ** ***** ******* until ******* researches *** **** ** guarantee its *************** citedBelluz * ****** Is *** ****** **** controversy *** ***** ** * terrifying *** chapter ** **** ******** Vox ****************************************************************************************** * ****** Everything *** **** to **** ***** ********* ****** ***** ******* *********** *** https://singularityhubcom/2019/11/05/everything-you-need-to-know-about-superstar-crispr-prime-editing/Rodriguez * (2016) ******* Issues in Genome ******* ***** *********** System ******* ** Clinical Research ***** ********* ****** **********************************************